Q-omics provides the consensus-scored PSMA4 profile across patient tissues and cancer cell-line models. PSMA4 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in LUAD. Among the 18 cancer types available for tumor–normal comparison, PSMA4 is differentially expressed in 13, with the highest sampling consensus in HNSC. Additionally, PSMA4 protein abundance shows 20,855 significant protein co-abundance associations, with the highest sampling consensus in HNSC. Together, these results highlight LUAD, and HNSC as cancer lineages where PSMA4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PSMA4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PSMA4 survival associations across molecular data types. PSMA4 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (4) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PSMA4 RNA expression–survival associations across cancer types. High PSMA4 expression shows unfavorable associations in LUAD, UVM, HNSC, ACC, MESO and KICH. The LUAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LUAD as the clearest survival context for PSMA4 RNA expression.
This table summarizes PSMA4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 6. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for PSMA4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PSMA4 shows higher tumor expression in HNSC, KIRC, STAD, BLCA, LIHC and LUSC. The HNSC box plot shows higher PSMA4 RNA expression in tumor versus normal tissue (log2 FC = +1.049, t-test p < 0.001).
This table shows molecular features associated with PSMA4 in patient tissues and cancer cell lines. In patient samples, PSMA4 shows the broadest associations at the RNA and protein expression levels, with HNSC recurring as the lineage with the largest associated feature set. In cancer cell lines, PSMA4 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia, while CRISPR and shRNA rows add functional-dependency signals in LUNG_SCLC and BLOOD_Lymphoma.
